Skip to main content

Advertisement

SpringerLink
Log in

Immunogenicity of advanced glycation end products in diabetic patients and in nephropathic non-diabetic patients on hemodialysis or after renal transplantation

  • Original Articles
  • Published:
Journal of Endocrinological Investigation Aims and scope Submit manuscript

Abstract

Advanced glycation end products (AGE) increase as a consequence of diabetic hyperglycemia and, in nephropathic patients, following renal function loss. Protein-bound AGE behave as immunogens, inducing formation of specific antibodies (Ab-AGE). In this work AGE immunogenicity was studied in 42 diabetic patients, 26 nephropathic patients on hemodialysis and 26 patients with end-stage renal disease who underwent kidney transplantation and in 20 normal subjects. Non-oxidation-derived AGE (nox-AGE), oxidation-derived AGE (ox-AGE) and Ab-AGE were measured by competitive or direct enzyme-linked immunosorbent assay (ELISA) and circulating immune complexes (CIC) by C1q ELISA. Nox-AGE increased significantly in all patient groups (p≤0.05 to ≤0.0001) except in patients on hemodialysis for less than 6 yr. Ox-AGE were only significantly increased in patients transplanted more than 3 yr previously (p<0.05). Ab-AGE were significantly lower than controls in both diabetic groups and in patients on hemodialysis for more than 6 yr (p<0.005 to <0.0001) and not unlike controls in the other groups. These results demonstrate that hemodialysis or renal tranplantation can, initially, reduce either nox- or ox-AGE levels, which however go back to being high in time. Renal transplantation fails to normalize nox-AGE. More importantly, plasma Ab-AGE levels are reduced or unchanged in all patient groups in comparison with controls, despite higher circulating AGE levels. This suggests the importance of tissue-bound AGE as Ab-AGE targets. Additional interventions are needed to control AGE levels in treated nephropathic patients. The search and quantification of specific Ab-AGE would give more meaningful results if performed over specific tissue specimens.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Subscribe and save

Springer+ Basic
$34.99 /Month
  • Get 10 units per month
  • Download Article/Chapter or eBook
  • 1 Unit = 1 Article or 1 Chapter
  • Cancel anytime
Subscribe now

Buy Now

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ahmed N. Advanced glycation end products — role in pathology of diabetic complications. Diabetes Res Clin Pract 2005, 67: 3–21.

    Article  PubMed  CAS  Google Scholar 

  2. Bohlender JM., Franke S, Stein G, Wolf G. Advanced glycation end products and the kidney. Am J Physiol Renal Physiol 2005, 289: 645–59.

    Article  CAS  Google Scholar 

  3. Henle T, Miyata T. Advanced glycation end products in uremia. Adv Ren Replace Ther 2003, 10: 321–31.

    Article  PubMed  Google Scholar 

  4. Kalousova M, Zima T, Tesar V, Stipek S, Sulkova S. Advanced glycation end products in clinical nephrology. Kidney Blood Press Res 2004, 27: 18–28.

    Article  PubMed  CAS  Google Scholar 

  5. Raj DS, Choudhury D, Welbourne TC, Levi M. Advanced glycation end products: a nephrologist’s perspective. Am J Kidney Dis 2000, 35: 365–80.

    Article  PubMed  CAS  Google Scholar 

  6. Shimoike T, Inoguchi T, Umeda F, Nawata H, Kawano K, Ochi H. The meaning of serum levels of advanced glycosylation end products in diabetic nephropathy. Metabolism 2000, 49: 1030–5.

    Article  PubMed  CAS  Google Scholar 

  7. Morena M, Delbosc S, Dupuy AM, Canaud B, Cristol JP. Overproduction of reactive oxygen species in end-stage renal diseases patients: a potential component of Hemodiaysis-associated inflammation. Hemodial Int 2005, 9: 37–46.

    Article  PubMed  Google Scholar 

  8. Vas T, Wagner Z, Jenei V, et al. Oxidative stress and non-enzymatic glycation in IgA nephropathy. Clin Nephrol 2005, 64: 343–51.

    Article  PubMed  CAS  Google Scholar 

  9. Sebekova K, Blazícek P, Syrová D, et al. Circulating advanced glycation end product levels in rats rapidly increase with acute renal failure. Kidney Int Suppl 2001, 78: S58–62.

    Article  PubMed  CAS  Google Scholar 

  10. Makita Z, Vlassara H, Cerami A, Bucala R. Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 1992, 267: 5133–8.

    PubMed  CAS  Google Scholar 

  11. Ikeda K, Nagai R, Sakamoto T, et al. Immunochemical approaches to AGE-structures: characterization of anti-AGE antibodies. J Immunol Methods 1998, 215: 95–104.

    Article  PubMed  CAS  Google Scholar 

  12. Buongiorno AM., Sagratella E, Morelli S, et al. Two policlonal antisera detect different AGE epitopes in human plasma samples. Immunol Lett 2003, 85: 243–9.

    Article  PubMed  CAS  Google Scholar 

  13. Buongiorno AM, Sagratella E, Morelli S, Di Virgilio A, Sensi M. Advanced glycosylation end product quantification: differently produced policlonal antisera do not share the recognition of epitopes of different nature. Ann 1st Super Sanità 2002, 38: 393–9.

    CAS  Google Scholar 

  14. Palinski W, Koschinsky T, Butler S, et al. Immunological evidence for the presence of advanced glycosylation end products in atherosclerotic lesions of euglycemic rabbits. Arterioscler Thromb Vasc Biol 1995, 95: 571–82.

    Article  Google Scholar 

  15. Shibayama R, Araki N, Nagai R, Horiuchi S. Autoantibody against Nε-(carboximethil)lysine, an advanced glycation end product of the Maillard reaction. Diabetes 1999, 48: 1842–9.

    Article  PubMed  CAS  Google Scholar 

  16. Araki N, Shibayama R, Ejima Y, et al. Study of autoantibodies against advanced glycation end products of the Maillard reaction. International Congress Series 2001, 1223: 49–58.

    Article  CAS  Google Scholar 

  17. Virella G, Thorpe S, Alderson N, et al. Autoimmune response to advanced glycosylation end products of human LDL. J Lipid Res 2003, 44: 487–93.

    Article  PubMed  CAS  Google Scholar 

  18. Turk Z, Ljubie S, Turk N, Benko B. Detection of auto-antibodies against advanced glycation end products and AGE-immunecomplexes in serum of patients with diabetes. Clin Chim Acta 2001, 303: 105–15.

    Article  PubMed  CAS  Google Scholar 

  19. Singh R, Barden A, Mori T, Beilin L. Advanced glycation end-products: a review. Diabetologia 2001, 44: 129–46.

    Article  PubMed  CAS  Google Scholar 

  20. Miyata T, Maeda K, Kurokawa K, van Ypersele de Strihou C. Oxidation conspires with glycation to generate noxious advanced glycation end products in renal failure. Nephrol Dial Transplant 1997, 12: 255–8.

    Article  PubMed  CAS  Google Scholar 

  21. Pulido JS. Experimental nonenzymatic glycosylation of vitreous collagens occurs by two pathways. Trans Am Ophthalmol Soc 1996, 94: 1029–72.

    PubMed Central  PubMed  CAS  Google Scholar 

  22. Nakayama H, Taneda S, Kuwajima S, et al. Production and characterization of antibodies to advanced glycation products on proteins. Biochem Biophys Res Commun 1989, 162: 740–5.

    Article  PubMed  CAS  Google Scholar 

  23. Nakayama H, Taneda S, Mitisuhashi T, et al. Characterization of antibodies to advanced glycosylation end products on protein. J Immunol Methods 1991, 140: 119–25.

    Article  PubMed  CAS  Google Scholar 

  24. Farboud B, Aotaki-Keen A, Miyata T, Hjelmeland L, Handa J. Development of a policlonal antibody with broad epitope specific for advanced glycation end products and localization of these epitopes in Brunch’s membrane of the aging eye. Mol Vis 1999, 5: 11–6.

    PubMed  CAS  Google Scholar 

  25. Hirata K and Kubo K. Relationship between blood level of N-Carboxymethyl-lysine and Pentosidine and the severity of microangiopathy in type 2 diabetes. Endocr J 2004, 51: 537–44.

    Article  PubMed  CAS  Google Scholar 

  26. Nakamura Y, Horii Y, Nishino T, et al. Immunohistochemical localization of advanced glycosylation end products in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 1993, 143: 1649–56.

    PubMed Central  PubMed  CAS  Google Scholar 

  27. Horie K, Miyata T, Maeda K, et al. Immunological colocalization of glycoxidation products and lipid peroxidation products in diabetic renal glomerular lesions, implication for glycoxidative stress in the pathogenesis of diabetic nephropathy. J Clin Invest 1997, 100: 2995–3004.

    Article  PubMed Central  PubMed  CAS  Google Scholar 

  28. Izuhara Y, Nangaku M, Inagi R, et al Renoprotective properties of angiotensin receptor blockers beyond blood pressure lowering. J Am Soc Nephrol 2005, 16: 3631–41.

    Article  PubMed  CAS  Google Scholar 

  29. Nangaku M, Miyata T, Sada T, et al. Anti-hypertensive agents inhibit in vivo the formation of advanced glycation end products and improve renal damage in a type 2 diabetic nephropathy rat model. J Am Soc Nephrol 2003, 14: 1212–22.

    Article  PubMed  CAS  Google Scholar 

  30. Coughlan MT, Thallas-Bonke V, Pete J, et al. Combination therapy with the advanced glycation end product cross-link breaker, alagebrium, and angiotensin converting enzyme inhibitors in diabetes: synergy or redundancy? Endocrinology 2007, 148: 886–95.

    Article  PubMed  CAS  Google Scholar 

  31. Forbes JM, Cooper ME, Thallas V, et al. Reduction of the accumulation of advanced glycation end products by ACE inhibition in experimental diabetic nephropathy. Diabetes 2002, 51: 3274–82.

    Article  PubMed  CAS  Google Scholar 

  32. Yamagishi S, Takeuchi M, Inoue H. Renoprotective effects of azelnidipine, a dihydropyridine-based calcium antagonist in advanced glycation end product (AGE)-injected rats. Int J Tissue React 2005, 27: 137–43.

    PubMed  CAS  Google Scholar 

  33. Wenzel RR. Renal protection in hypertensive patients: selection of antihypertensive therapy. Drugs 2005, 65 (Suppl 2): 29–39.

    PubMed  CAS  Google Scholar 

  34. Kalousova M, Zima T, Tesar V, Stipek S, Sulkova S. Advanced glycation end products in clinical nephrology. Kidney Blood Press Res 2004, 27: 18–28.

    Article  PubMed  CAS  Google Scholar 

  35. Hartog JW, Smit AJ, van Son WJ, et al. Advanced glycation end products in kidney transplant patients: a putative role in the development of chronic renal transplant dysfunction. Am J Kidney Dis 2004, 43: 966–75.

    Article  PubMed  CAS  Google Scholar 

  36. Sensi M, Morano S, Sagratella E, et al. Advanced glycation end product levels in eye lenses, aorta, and tail tendon in transplanted diabetic inbred Lewis rats. Transplantation 2001, 72: 1370–5.

    Article  PubMed  CAS  Google Scholar 

  37. Sensi M, Morano S, Morelli S, et al. Reduction of advanced glycation end-product (AGE) levels in nervous tissue proteins of diabetic Lewis rats following islet transplants is related to different durations of poor metabolic control. Eur J Neurosci 1998, 10: 2768–75.

    Article  PubMed  CAS  Google Scholar 

  38. Vas T, Wagner Z, Jenei V, et al. Oxidative stress and non-enzymatic glycation in IgA nephropathy. Clin Nephrol 2005, 64: 343–51.

    Article  PubMed  CAS  Google Scholar 

  39. Sebekova K, Blazicek P, Syrova D, et al. Circulating advanced glycation end product levels in rats rapidly increase with acute renal failure. Kidney Int Suppl 2001, 78: S58–62.

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Hematology, Oncology and Molecular Medicine, National Institute of Health, Italy

    A. M. Buongiorno PhD, S. Morelli & E. Sagratella

  2. Department of Clinical Sciences, University of Rome “Sapienza”, Rome, Italy

    R. Cipriani, S. Mazzaferro, S. Morano & M. Sensi

Authors
  1. A. M. Buongiorno PhD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. S. Morelli
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. E. Sagratella
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. R. Cipriani
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. S. Mazzaferro
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. S. Morano
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. M. Sensi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. M. Buongiorno PhD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Buongiorno, A.M., Morelli, S., Sagratella, E. et al. Immunogenicity of advanced glycation end products in diabetic patients and in nephropathic non-diabetic patients on hemodialysis or after renal transplantation. J Endocrinol Invest 31, 558–562 (2008). https://doi.org/10.1007/BF03346408

Download citation

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03346408

Key-words

Search

Navigation